The Lucile Packard Children's Hospital aims to improve health through leadership, diversity, and collaborative discoveries and innovation in health care, education and research.
The Bass Center for Childhood Cancer and Blood Diseases, which is ranked by the U.S. News & World Report and part of the Stanford Cancer Institute, an NCI-designated comprehensive cancer center, aims to help young people with pediatric cancer and blood diseases manage or overcome their medical conditions. With a fully integrated inpatient/outpatient environment and a world-class faculty and staff, the Bass Center provides an ideal environment for delivering the best possible care for children, adolescents, and young adults with blood diseases and cancer. The center is designed to create a hopeful, healing environment by moving most services for cancer and blood diseases to one physical location in the hospital, expediting care delivery and ensuring optimal care coordination. The Bass Center includes inpatient facilities, a clinic, an onsite laboratory, a fully equipped day hospital, a procedure unit with general anesthesia capability and a specialized pharmacy. Alongside this, the Bass Center also has dedicated research programs in cancer, blood diseases, stem cell transplantation (SCT) and regenerative medicine.
Norman Lacayo, MD
Norman Lacayo, MD received his BA in Biochemistry from UC Berkeley, and his MD from UC San Francisco School of Medicine (UCSF). He completed his residency in Pediatrics at UCSF and fellowship in Pediatric Hematology/Oncology/Stem Cell Transplantation at Stanford University. Dr. Lacayo is currently an Associate Professor of Pediatrics, a member of the Stanford Cancer Institute, and Lucile Packard Children's Hospital Stanford (LPCHS). At LPCHS he is the Co-Director of the Leukemia Program and Interim Oncology Section Leader. Dr. Lacayo's research focuses on the discovery and evaluation of new biomarkers in childhood acute leukemia. He actively collaborates with the Children's Oncology Group, led the ADVL0114 study using Decitabine for relapse and refractory leukemia, and is currently a member of the COG Myeloid Committee. Also participated in the St. Jude AML Consortium Trials AML02, AML08 and AML16. Dr. Lacayo became the first institutional PI for the Pediatric Oncology Experimental Therapies Investigational Consortium (POETIC) group in October 2015.
"Our institution and POETIC consortium provide a nurturing environment that makes collaboration easy, and quickly brings new therapies for children at all our sites."
-Dr. Norman Lacayo
Allie Pribnow, MD, MPH
Dr. Pribnow, MD, MPH received her BA in Spanish Foreign Language & Literature from Whitman College, her MPH from Oregon State University, and her MD from Oregon Health & Sciences University (OHSU). She completed her residency training in Pediatrics at Stanford University and her fellowship in Pediatric Hematology/Oncology at St. Jude Children’s Research Hospital. Dr. Pribnow is currently a Clinical Assistant Professor at Stanford University and an attending physician at Lucile Packard Children’s Hospital Stanford (LPCHS). She is the Co-Chair of the Local Improvement Team for the Bass Center for Childhood Cancer & Blood Diseases at LPCHS and of the Chemotherapy Safety Committee. Dr. Pribnow is a member of the Children’s Oncology Group (COG) and currently serving as the COG Adolescent and Young Adult (AYA) Responsible Investigator for the LPCHS site. She has a clinical concentration in solid tumors with a focus on management of bone sarcomas. Her academic interests include treatment of recurrent/refractory OS and EWS, AYA oncology and global oncology.
Eileen Monge, RN, BSN
Eileen graduated from Mount Saint Mary's University in Los Angeles with a BS in Nursing. She started her career at UCSF in pediatric critical care and bone marrow transplant. From that experience she went on to work for several years as a research nurse in pediatric and adult solid organ transplant. Most recently she worked in the biotechnology industry at Genentech, engaged in the development and deployment of phase I-IV clinical trials. Much of her focus at Genentech was on phase I-II clinical trials for solid tumors. She was a subject matter expert and collaborated on the Common Terminology Criteria for Adverse Events, (CTCAE) for version 4.0, to align the CTCAE with Medical Dictionary for Regulatory Affairs, (MedDRA). She has collaborated with MedDRA and presented at Blue Ribbon Panels on capturing adverse events in clinical trials and pharmacovigilance.
Namrata Patel, PharmD
Namrata joined the pharmacy team at Lucile Packard Children's Hospital at Stanford in 2010 and has since become the Investigational Drug Pharmacist for the Divisions of Hematology/Oncology and Stem Cell Transplantation and Regenerative Medicine. Dr. Patel is a graduate of the University of North Carolina at Chape Hill. She completed a residency at UCSF in 2010. Namrata obtained her Pharmacy Board Certification in Oncology (BCOP) in 2017. She works with all early phase trials at LPCHS to include New Approaches to Neuroblastoma Therapy (NANT) Consortium, the Pediatric Brain Tumor Consortium (PBTC) and participates in St. Jude Children's Research Hospital studies and numerous industry sponsored studies. Dr. Patel is the COG Study Pharmacist (Protocol ACNS1721) and is a pharmacy consultant for the American Association of Blood Banks (AABB) Medication Deferral List Task Force.
The research team at Lucile Packard Children’s Hospital